Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 1
2015 2
2016 5
2017 4
2018 2
2019 11
2020 11
2021 7
2022 5
2023 10
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go?
Alfieri S, Romanò R, Marceglia S, De Giorgi V, Peris K, Sollena P, Piccerillo A, Moro R, Gualdi G, Ascierto PA, Palla M, Paone M, Eibenschutz L, Spagnolo F, Queirolo P, Filippini DM, Cavalieri S, Resteghini C, Bergamini C, Manocchio A, Licitra L, Bossi P. Alfieri S, et al. Among authors: resteghini c. Oncologist. 2024 May 3;29(5):e699-e707. doi: 10.1093/oncolo/oyad319. Oncologist. 2024. PMID: 38127280 Free article.
Multidisciplinary management of pregnancy-associated and early post-partum head and neck cancer patients.
Bergamini C, Cavalieri S, Resteghini C, Alfieri S, Nuzzolese I, Colombo E, Ottini A, Calareso G, Vingiani A, Iacovelli NA, Franceschini M, Guzzo M, Deganello A, Licitra L. Bergamini C, et al. Among authors: resteghini c. Front Oncol. 2023 Nov 22;13:1298439. doi: 10.3389/fonc.2023.1298439. eCollection 2023. Front Oncol. 2023. PMID: 38074678 Free PMC article.
Tumor molecular landscape of Epstein-Barr virus (EBV) related nasopharyngeal carcinoma in EBV-endemic and non-endemic areas: Implications for improving treatment modalities.
Lenoci D, Resteghini C, Serafini MS, Pistore F, Canevari S, Ma B, Cavalieri S, Alfieri S, Trama A, Licitra L, De Cecco L. Lenoci D, et al. Among authors: resteghini c. Transl Res. 2024 Mar;265:1-16. doi: 10.1016/j.trsl.2023.10.004. Epub 2023 Nov 8. Transl Res. 2024. PMID: 37949350 Free article.
Head and neck cancers survival in Europe, Taiwan, and Japan: results from RARECAREnet Asia based on a privacy-preserving federated infrastructure.
Botta L, Matsuda T, Charvat H, Chiang CJ, Lee WC, van Gestel AJ, Martin F, Geleijnse G, Cellamare M, Bonfarnuzzo S, Marcos-Gragera R, Guevara M, Mousavi M, Craig S, Rodrigues J, Rubió-Casadevall J, Licitra L, Cavalieri S, Resteghini C, Gatta G, Trama A; RARECAREnet working group. Botta L, et al. Among authors: resteghini c. Front Oncol. 2023 Sep 13;13:1219111. doi: 10.3389/fonc.2023.1219111. eCollection 2023. Front Oncol. 2023. PMID: 37781187 Free PMC article.
Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experience.
Cavalieri S, Platini F, Barretta F, Nuzzolese I, Ottini A, Bergamini C, Resteghini C, Colombo E, Iacovelli NA, Franceschini M, Calareso G, Di Pede P, De Feo G, Gandelli M, Toffolatti L, Guglielmo M, Ripamonti CI, Cosmai L, Licitra L, Alfieri S. Cavalieri S, et al. Among authors: resteghini c. Oral Oncol. 2023 Nov;146:106579. doi: 10.1016/j.oraloncology.2023.106579. Epub 2023 Sep 29. Oral Oncol. 2023. PMID: 37778228
The SINTART 1 study. A phase II non-randomised controlled trial of induction chemotherapy, surgery, photon-, proton- and carbon ion-based radiotherapy integration in patients with locally advanced resectable sinonasal tumours.
Resteghini C, Castelnuovo P, Nicolai P, Orlandi E, Bossi P, Vischioni B, Schreiber A, Gambazza S, Iacovelli NA, Battaglia P, Guzzo M, Turri-Zanoni M, Mattavelli D, Facchinetti N, Calareso G, Ravanelli M, Facco C, Tartaro T, Licitra L. Resteghini C, et al. Eur J Cancer. 2023 Jul;187:185-194. doi: 10.1016/j.ejca.2023.03.033. Epub 2023 Apr 5. Eur J Cancer. 2023. PMID: 37164774 Clinical Trial.
The SINTART 2 Study. A phase II non-randomised controlled trial of induction chemotherapy, photon-, proton- and carbon-ion-based radiotherapy integration in patients with locally advanced unresectable sinonasal tumours.
Bossi P, Orlandi E, Resteghini C, Vischioni B, Nicolai P, Castelnuovo P, Gambazza S, Locati LD, Turri-Zanoni M, Ferrari M, Facchinetti N, Iacovelli NA, Calareso G, Quattrone P, Cavallo A, Tuzi A, Licitra L. Bossi P, et al. Among authors: resteghini c. Eur J Cancer. 2023 Jul;187:134-143. doi: 10.1016/j.ejca.2023.03.034. Epub 2023 Apr 7. Eur J Cancer. 2023. PMID: 37163806 Clinical Trial.
The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports.
Colombo E, Gurizzan C, Ottini A, Caspani F, Bergamini C, Locati LD, Marchiselli C, Alberti A, Lorini L, Licitra LF, Bossi P, Resteghini C. Colombo E, et al. Among authors: resteghini c. Front Oncol. 2023 Feb 28;13:1111146. doi: 10.3389/fonc.2023.1111146. eCollection 2023. Front Oncol. 2023. PMID: 36925925 Free PMC article.
A multicenter randomized trial for quality of life evaluation by non-invasive intelligent tools during post-curative treatment follow-up for head and neck cancer: Clinical study protocol.
Cavalieri S, Vener C, LeBlanc M, Lopez-Perez L, Fico G, Resteghini C, Monzani D, Marton G, Pravettoni G, Moreira-Soares M, Filippidou DE, Almeida A, Bilbao A, Mehanna H, Singer S, Thomas S, Lacerenza L, Manfuso A, Copelli C, Mercalli F, Frigessi A, Martinelli E, Licitra L; BD4QoL Consortium. Cavalieri S, et al. Among authors: resteghini c. Front Oncol. 2023 Jan 31;13:1048593. doi: 10.3389/fonc.2023.1048593. eCollection 2023. Front Oncol. 2023. PMID: 36798825 Free PMC article.
51 results